- Home
- XCUR
XCUR
Exicure Inc.
as 11-22-2024 4:00pm EST
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 12.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.44 - $19.62 | Next Earning Date: | 11-14-2024 |
| Revenue: | $500,000 | Revenue Growth: | -97.70% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Exicure Inc. (XCUR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DGP Co., Ltd. | XCUR | 10% Owner | Sep 12 '24 | Buy | $3.00 | 237,223 | $711,669.00 | 849,223 |
Latest Exicure Inc. News
XCUR Breaking Stock News: Dive into XCUR Ticker-Specific Updates for Smart Investing
Business Wire
10 days ago
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
Business Wire
2 months ago
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
Business Wire
2 months ago
Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation
Business Wire
3 months ago
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
Business Wire
3 months ago
Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
Business Wire
3 months ago
Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
Business Wire
3 months ago
Exicure, Inc. Reports Second Quarter 2024 Financial Results
Business Wire
4 months ago
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
Compare XCUR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XCUR Exicure Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.